Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages

Accumulation of tumor-associated macrophages (TAM) correlates with malignant progression, immune suppression, and poor prognosis. In this study, we defined a critical role for the cell-surface guidance molecule SEMA3A in differential proliferative control of TAMs. Tumor cell-derived SEMA3A restricte...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 76; no. 11; pp. 3166 - 3178
Main Authors Wallerius, Majken, Wallmann, Tatjana, Bartish, Margarita, Östling, Jeanette, Mezheyeuski, Artur, Tobin, Nicholas P, Nygren, Emma, Pangigadde, Pradeepa, Pellegrini, Paola, Squadrito, Mario Leonardo, Pontén, Fredrik, Hartman, Johan, Bergh, Jonas, De Milito, Angelo, De Palma, Michele, Östman, Arne, Andersson, John, Rolny, Charlotte
Format Journal Article
LanguageEnglish
Published United States 01.06.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Accumulation of tumor-associated macrophages (TAM) correlates with malignant progression, immune suppression, and poor prognosis. In this study, we defined a critical role for the cell-surface guidance molecule SEMA3A in differential proliferative control of TAMs. Tumor cell-derived SEMA3A restricted the proliferation of protumoral M2 macrophages but increased the proliferation of antitumoral M1, acting through the SEMA3A receptor neuropilin 1. Expansion of M1 macrophages in vivo enhanced the recruitment and activation of natural killer (NK) cells and cytotoxic CD8(+) T cells to tumors, inhibiting their growth. In human breast cancer specimens, we found that immunohistochemical levels of SEMA3A correlated with the expression of genes characteristic of M1 macrophages, CD8(+) T cells, and NK cells, while inversely correlating with established characters of malignancy. In summary, our results illuminate a mechanism whereby the TAM phenotype is controlled and identify the cell-surface molecule SEMA3A as a candidate for therapeutic targeting. Cancer Res; 76(11); 3166-78. ©2016 AACR.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0008-5472
1538-7445
1538-7445
DOI:10.1158/0008-5472.can-15-2596